Search results for "Arm"

showing 10 items of 19046 documents

Safety and potential interaction of immunosuppressive drugs for the treatment of inflammatory bowel disease in elderly patients

2021

Inflammatory bowel diseases, including Crohn's disease and ulcerative colitis, are chronic diseases associated with increased morbidity and reduced quality of life. Age may represent a risk factor for adverse events, due to the multimorbidity and polypharmacy, common in elderly patients. Elderly are often not included in clinical trials evaluating efficacy and safety of study drugs for the treatment of inflammatory bowel diseases. Several drugs, such as aminosalicylates, systemic corticosteroids, immunosuppressant drugs, biological drugs and Janus Kinase inhibitors, are available for the management of inflammatory bowel diseases. With the increasing spectrum of therapeutic options, it is th…

safetyPolypharmacydrug-drug interactionsmedicine.medical_specialtybusiness.industryEndocrinology Diabetes and MetabolismInflammatory bowel disease elderly patients safety drug-drug interactionsGastroenterologyDiseaseelderly patientsmedicine.diseaseInflammatory bowel diseaseUlcerative colitisInflammatory bowel diseaseVedolizumabClinical trialUstekinumabInternal MedicinemedicineAdverse effectIntensive care medicinebusinessmedicine.drugMinerva Gastroenterology
researchProduct

Combined hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Hemophilus influenzae type b vaccine; Infanrix™ hexa: T…

2014

Infant vaccination using 2-dose priming at 3 and 5 mo of age with a booster at 11–12 mo of age was pioneered in Italy. The 3-5-11 schedule is now used in a growing number of European countries. Infanrix™ hexa (DTPa-HBV-IPV/Hib, GlaxoSmithKline Vaccines) was first licensed for use in 2000 and has been the only pediatric hexavalent vaccine available since 2005. We reviewed available clinical trial data describing the immunogenicity of DTPa-HBV-IPV/Hib when administered at 3, 5, and 11 mo of age, and conducted an analysis of safety using global and Italian post-marketing surveillance data. In Italy, DTPa-HBV-IPV/Hib has a demonstrated safety record extending over a decade of use, it has been a…

safetybooster vaccination; combination vaccines; hexavalent vaccine; immunogenicity; Italy; primary vaccination; safety; Clinical Trials as Topic; Diphtheria-Tetanus-Pertussis Vaccine; Haemophilus Vaccines; Hepatitis B Vaccines; Humans; Italy; Poliovirus Vaccine Inactivated; Product Surveillance Postmarketing; Vaccination; Vaccines Combined; Medicine (all)Settore MED/42 - Igiene Generale e ApplicataImmunologySocio-culturaleReviewimmunogenicitySettore MED/42 - Igiene Generale E Applicatamedicine.disease_causeprimary vaccinationProduct Surveillance PostmarketingmedicineImmunology and AllergyHumansHepatitis B VaccinesVaccines CombinedDiphtheria-Tetanus-Pertussis VaccineHaemophilus VaccinesPharmacologycombination vaccinesbooster vaccination; combination vaccines; hexavalent vaccine; immunogenicity; Italy; primary vaccination; safety; Medicine (all)Clinical Trials as TopicVaccinescombination vaccineTetanusbusiness.industryCombinedImmunogenicityPoliovirusDiphtheriaMedicine (all)VaccinationInactivatedHepatitis Bmedicine.diseaseVirologyProduct SurveillancePostmarketingClinical trialVaccinationPoliovirus Vaccinebooster vaccinationPoliovirus Vaccine InactivatedInfanrix hexaItalyhexavalent vaccine; primary vaccination; booster vaccination; Italy; combination vaccines; immunogenicity; safetybusinesshexavalent vaccine
researchProduct

Efficacy of Long-Term Treatment of Autosomal Recessive Hypercholesterolemia With Lomitapide: A Subanalysis of the Pan-European Lomitapide Study

2022

Backgroundand aim: Autosomal recessive hypercholesterolemia (ARH) is a rare autosomal recessive disorder of low-density lipoprotein (LDL) metabolism caused by pathogenic variants in the LDLRAP1 gene. Like homozygous familial hypercholesterolemia, ARH is resistant to conventional LDL-lowering medications and causes a high risk of atherosclerotic cardiovascular diseases (ASCVDs) and aortic valve stenosis. Lomitapide is emerging as an efficacious therapy in classical HoFH, but few data are available for ARH.Results: This is a subanalysis carried out on nine ARH patients included in the Pan-European Lomitapide Study. The age at starting lomitapide was 46 (interquartile range (IQR), 39.0–65.5) y…

safetylomitapidelong-termsafety.Settore MED/09 - Medicina Internaefficacyrare diseaseReal-world studySDG 3 - Good Health and Well-beingSettore BIO/14 - FarmacologiaGeneticsMolecular MedicineLDL-C; Real-world study; autosomal recessive hypercholesterolaemia; efficacy; lomitapide; long-term; rare disease; safetyautosomal recessive hypercholesterolaemiaLDL-CGenetics (clinical)
researchProduct

Tenapanor for the treatment of irritable bowel syndrome with constipation.

2020

Introduction: Irritable bowel syndrome with constipation is associated with higher rates of functional impairment, as compared to other subtypes of the syndrome. Conventional laxative-based pharmacologic therapy of IBS-C, which is mostly symptom-based, is often unsatisfactory. Tenapanor represents a first-in-class orally available inhibitor of NHE3, which is minimally absorbed in the GI tract, what constitutes a significant therapeutic benefit, as it may act on the drug target. Areas covered: Aim of this article is to sum up the evidences about pharmacodynamics and pharmacokinetics of tenapanor, focusing on animal models and in vitro studies, but also discuss clinical trials on tenapanor's …

safetymedicine.medical_specialtyFunctional impairmentConstipationmedicine.medical_treatmentefficacyLaxative030226 pharmacology & pharmacyGastroenterologyIrritable Bowel Syndrome03 medical and health scienceschemistry.chemical_compound0302 clinical medicineGastrointestinal AgentsInternal medicinemedicineAnimalsHumansPharmacology (medical)Pharmacologic therapyDrug InteractionsGeneral Pharmacology Toxicology and PharmaceuticsTenapanorIrritable bowel syndromeSulfonamidesbusiness.industrySodium-Hydrogen Exchanger 3General Medicinemedicine.diseaseIsoquinolinestenapanor.chemistry030220 oncology & carcinogenesismedicine.symptombusinessConstipationExpert review of clinical pharmacology
researchProduct

Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multi…

2018

BACKGROUND: The aim of the study was to evaluate the achievement of 'no evidence of disease activity' (NEDA) over a 12-month period in a large multicenter population with relapsing remitting multiple sclerosis (RRMS) treated with delayed-release dimethyl fumarate (DMF) and teriflunomide (TRF) using a propensity-score adjustment. METHODS: A time-to-event method was used to determine the percentages of patients with RRMS (pwRRMS) in both groups achieving NEDA 3 (no relapses, no 12-week confirmed disability progression, and no new T2/gadolinium-enhancing brain lesions). We described the safety profile of the investigated drugs. RESULTS: Of the 587 pwRRMS treated with DMF and the 316 pwRRMS tre…

safetymedicine.medical_specialtydimethyl fumarate; efficacy; no evidence of disease activity 3; safety; teriflunomide; pharmacology; neurology; neurology (clinical)Populationefficacylcsh:RC346-429Disease activity03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineTeriflunomideteriflunomideMedicine030212 general & internal medicineno evidence of disease activity 3educationlcsh:Neurology. Diseases of the nervous systemOriginal ResearchPharmacologyeducation.field_of_studydimethyl fumarateDimethyl fumaratebusiness.industryMultiple sclerosismedicine.diseasechemistryRelapsing remittingNeurologySettore MED/26 - NeurologiaReal wordNeurology (clinical)business030217 neurology & neurosurgerydimethyl fumarate; efficacy; no evidence of disease activity 3; safety; teriflunomide
researchProduct

Organisaation merkityksentäminen sairaalajohtoryhmäkokouksissa

2016

Kokouksia järjestetään kaikissa organisaatioissa ja yhteiskunnissa ja ne vievät valmisteluineen suuren osan erityisesti johtajien työajasta. Tästä huolimatta kokousten roolia osana organisaation prosesseja on tutkittu ja jäsennetty teoreettisesti verrattain vähän. Tämä tutkimus keskittyy sairaalajohtoryhmien kokousvuorovaikutuksessa tapahtuvaan sairaalaorganisaation merkityksentämiseen (sensemaking). Tutkimuksen tavoite on ymmärtää johtoryhmien kokousvuorovaikutuksessa tapahtuvan sairaalaorganisaation merkityksentämisen roolia osana kokouksia ja koko organisaation toimintaa. Aineistona on kymmenen videoitua kokousta kahdelta eri organisaatiotasolta. Aineiston analyysi perustui vuorovaikutus…

sairaalasairaalatvuorovaikutuskokouksetkokousmerkityksetPharmacology (medical)merkityksentäminenArtikkelitjohtoryhmätPrologi
researchProduct

Vuorovaikutus sairaalajohtoryhmien kokouksissa

2018

Lectio praecursoria viestinnän väitöskirjaksi tarkoitetun tutkimuksen Vuorovaikutus sairaalajohtoryhmien kokouksissa tarkastustilaisuudessa Jyväskylän yliopistossa 27.10.2018. Vastaväittäjänä toimi vanhempi yliopistonlehtori, dosentti Pekka Pälli (Aalto yliopisto) ja kustoksena yliopistonlehtori, FT Leena Mikkola (Jyväskylän yliopisto). nonPeerReviewed

sairaalatvuorovaikutusLectio praecursoriaterveysalaPharmacology (medical)
researchProduct

Sairaalatyöyhteisön hallinnollisessa vuorovaikutuksessa rakennetaan työn resursseja ja työn yhteisyyttä

2018

Lectio praecursoria viestinnän väitöskirjaksi tarkoitetun tutkimuksen Hallinnollinen vuorovaikutus sairaalatyöyhteisössä tarkastustilaisuudessa Jyväskylän yliopistossa 6.4.2018. Vastaväittäjänä toimi yliopistonlehtori, dosentti Tuula-Riitta Välikoski (Tampereen yliopisto) ja kustoksena yliopistonlehtori, FT Leena Mikkola (Jyväskylän yliopisto). nonPeerReviewed

sairaalatvuorovaikutusLectio praecursoriayhteisöllisyysterveysalaPharmacology (medical)resurssittyöPrologi
researchProduct

Warming temperatures and ectoparasitic sea lice impair internal organs in juvenile Atlantic salmon

2021

As a consequence of climate change and open net-pen salmon farming, wild Atlantic salmon Salmo salar are increasingly likely to encounter elevated temperatures and parasite abundances during their early marine migration. Such stressors can compromise fitness by diminishing liver energy stores and impairing cardiac muscle. To assess whether temperature and infestation by salmon lice Lepeophtheirus salmonis are important correlates of liver energy stores and cardiac muscle performance in juvenile salmon, we experimentally infested fish at 3 abundances of louse infestation (zero, low, and high) and 5 temperatures (10, 13, 16, 19, and 22°C). At the end of the experiment (i.e. when sea lice reac…

salmon farmslohiheartparasitismikalatäitilmastonmuutoksetliverclimate changekalanviljelyaquacultureLepeophtheirus salmonisloisetparasitic diseasescardiosomatic indexhepatosomatic indexlämpötilalämpeneminenfysiologiset vaikutukset
researchProduct

Holesterīnu pazeminošo uztura bagātinātāju zinātniskā pamatojuma izvērtējums

2019

Paaugstināts holesterīna līmenis ir problēma, kas mūsdienās skar arvien vairāk cilvēku. Hiperholesterinēmija var radīt aterosklerozi, kas ir patoloģiskais pamats vairumam sirds un asinsvadu slimību, tostarp miokarda infarkta, insulta un perifēro artēriju slimību attīstībai. Aterosklerotisko bojājumu veidošanās ir hronisks process, ko raksturo pārmērīgas holesterīna nogulsnes artēriju sieniņās. Hiperlipidēmijas samazināšanai būtiski ir dzīvesveida maiņa, bet plaši tiek lietoti arī uztura bagātinātāji, kuru sastāvā aktīvā viela ir monakolīns K. Darba mērķis ir izpētīt, vai holesterīnu pazeminošiem uztura bagātinātājiem ir zinātniskais pamatojums. Ar anketēšanas palīdzību tika noteikti sabiedr…

sarkanā rauga rīsu ekstraktslipoproteīniuztura bagātinātājiFarmācijastatīniholesterīns
researchProduct